ADCC, antibody-dependent cell mediated cytotoxicity; ALDH, alcohol dehydrogenase; AML, acute myeloid leukemia; ARID3B, AT-rich interaction domain-containing protein 3B; CCR7, C­C motif chemokine receptor 7; CIK, cytokine-induced killer cell; CMV, cytomegalovirus; CSC, cancer stem cell; CTL, cytotoxic T lymphocytes; CTLA-4, cytotoxic T-cell-associated antigen-4; Cancer stem cells; DC, dendritic cell; DNMT, DNA methyltransferase; EMT, epithelial­mesenchymal transition; ETO, fat mass and obesity associated protein; EV, extracellular vesicle; HNSCC, head and neck squamous cell carcinoma; Immune checkpoints; Immune evasion; KDM4, lysine-specific demethylase 4C; KIR, killer immunoglobulin-like receptor; LAG3, lymphocyte activation gene 3; LILR, leukocyte immunoglobulin-like receptor; LMP, low molecular weight protein; LOX, lysyl oxidase; MDSC, myeloid-derived suppressor cell; MHC, major histocompatibility complex; MIC, MHC class I polypeptide-related sequence; NGF, nerve growth factor; NK cells; NK, natural killer; NOD, nonobese diabetic; NSG, NOD/SCID IL-2 receptor gamma chain null; OCT4, octamer-binding transcription factor 4; PD-1, programmed death receptor-1; PD-L1/2, ligands 1/2; PI9, protease inhibitor 9; PSME3, proteasome activator subunit 3; SCID, severe combined immunodeficient; SOX2, sex determining region Y-box 2; T cells; TAM, tumor-associated macrophage; TAP, transporter associated with antigen processing; TCR, T cell receptor; Treg, regulatory T cell; ULBP, UL16 binding protein; uPAR, urokinase-type plasminogen activator receptor